Phase II ADAPT Trial in Patients With HER2+ and HR+ Early Breast Cancer
Douglas Yee, MD, professor of medicine and pharmacology, Hematology, Oncology and Transplantation, Department of Medicine, medical oncologist, University of Minnesota, discusses the results of the phase II ADAPT trial.
Yee describes how the clinical trial evaluated the triple positive subgroup of women, with an endpoint of pathologic complete response. The rate was high for both T-DM1 and the addition of endocrine therapy. However, the rate was very low for the combination of trastuzumab and endocrine therapy.
Douglas Yee, MD, professor of medicine and pharmacology, hematology, oncology and transplantation, Department of Medicine, medical oncologist, University of Minnesota, discusses the results of the phase II ADAPT trial. It showed promise for chemotherapy-free neoadjuvant treatment with T-DM1 in patients who have HER2+ and HR+ early breast cancer.
Sequencing Sacituzumab and Other Drugs in HR+, HER2- Breast Cancer
May 16th 2024During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed multiple later-line treatment options in hormone receptor–positive breast cancer with participants in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
